Eye Disease & Ophthalmology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

This Phase 3 trial is testing a new port delivery system for ranibizumab, a medication used to treat diabetic macular edema, a common cause of vision loss in people with diabetes. The port delivery system is designed to release medication slowly over time, which could reduce how often patients need eye injections. If successful, this would make treatment less frequent and more convenient for patients managing this condition. The study is currently active but not recruiting, with results expected after a longer follow-up period.

Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

This Phase 3 study focuses on a gene therapy called voretigene neparvovec for Japanese patients with a rare inherited retinal disease caused by mutations in the RPE65 gene. Unlike treatments that only manage symptoms, this gene therapy aims to address the underlying genetic cause of vision loss. The study has completed enrolling participants and is awaiting results, which could offer new hope for patients living with this progressive condition in Japan.

Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression: A Randomized Controlled Trial

This Phase 3 trial is testing different low doses of atropine eye drops to slow the progression of myopia, or nearsightedness, in children and adolescents aged 6 to 18 years. Slowing myopia progression is important because severe nearsightedness can lead to complications later in life. Conducted in Pakistan, this study could identify safer and more effective ways to protect children’s vision. Results are expected by the end of 2026.

Sanitation, Water, and Instruction in Face-washing for Trachoma I/II

This Phase 3 trial is exploring how improving water, sanitation, and hygiene practices combined with antibiotics can reduce trachoma infections in children. Trachoma is an infectious eye disease that can cause blindness, especially in low-resource settings. Conducted in Ethiopia, the study involves large community participation and aims to find sustainable methods to control this preventable cause of blindness over several years.

Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)

This Phase 4 trial is testing a new injection treatment regimen for adults with diabetic macular edema who have not received prior treatment. The study aims to determine if this new approach can improve vision and reduce swelling in the eye more effectively than current methods. Recruiting in China, this trial could offer a more convenient and potentially better treatment option for patients with diabetes-related eye problems.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.